Last reviewed · How we verify
Lisinopril + HCTZ
Lisinopril inhibits angiotensin-converting enzyme to reduce blood pressure, while HCTZ is a thiazide diuretic that lowers blood pressure by reducing fluid volume and sodium reabsorption.
Lisinopril inhibits angiotensin-converting enzyme to reduce blood pressure, while HCTZ is a thiazide diuretic that lowers blood pressure by reducing fluid volume and sodium reabsorption. Used for Hypertension, Heart failure with reduced ejection fraction.
At a glance
| Generic name | Lisinopril + HCTZ |
|---|---|
| Also known as | Prinivil, Hydrochlorothiazide |
| Sponsor | St. Paul Heart Clinic |
| Drug class | ACE inhibitor + thiazide diuretic combination |
| Target | Angiotensin-converting enzyme (ACE); sodium-chloride cotransporter (NCCT) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Lisinopril blocks ACE, preventing conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone secretion. HCTZ acts as a thiazide diuretic, increasing urinary sodium and water excretion to decrease blood volume and peripheral vascular resistance. Together, these complementary mechanisms provide synergistic antihypertensive effects.
Approved indications
- Hypertension
- Heart failure with reduced ejection fraction
Common side effects
- Cough
- Dizziness
- Hyperkalemia
- Hypokalemia
- Hyperuricemia
- Hypotension
- Fatigue
Key clinical trials
- Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension (PHASE4)
- Genetics of Hypertension Associated Treatments (GenHAT)
- Polypill Effects on Sub Clinical Atherosclerosis (PESCA) Trial (PHASE3)
- Single Pill to Avert Cardiovascular Events (PHASE3)
- N-of-1 Trials In Children With Hypertension (PHASE4)
- The Precision Hypertension Care Study (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- CAndesartan vs LIsinopril Effects on the BRain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lisinopril + HCTZ CI brief — competitive landscape report
- Lisinopril + HCTZ updates RSS · CI watch RSS
- St. Paul Heart Clinic portfolio CI